MA45172B1 - Arn modifié codant pour des polypeptides vegf-a, formulations et utilisations associées - Google Patents

Arn modifié codant pour des polypeptides vegf-a, formulations et utilisations associées

Info

Publication number
MA45172B1
MA45172B1 MA45172A MA45172A MA45172B1 MA 45172 B1 MA45172 B1 MA 45172B1 MA 45172 A MA45172 A MA 45172A MA 45172 A MA45172 A MA 45172A MA 45172 B1 MA45172 B1 MA 45172B1
Authority
MA
Morocco
Prior art keywords
modified rna
formulations
polypeptides
rna encoding
encoding vegf
Prior art date
Application number
MA45172A
Other languages
English (en)
Other versions
MA45172A (fr
Inventor
Leif Karlsson Parinder
Danielson Regina Desirée Fritsche
Kenny Mikael Hansson
Li Ming Gan
Jonathan Clarke
Ann-Charlotte Eva Egnell
Kenneth Randall Chien
Original Assignee
Modernatx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modernatx Inc filed Critical Modernatx Inc
Publication of MA45172A publication Critical patent/MA45172A/fr
Publication of MA45172B1 publication Critical patent/MA45172B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons

Abstract

L'invention concerne des molécules d'arn modifiées codant pour des polypeptides vegf-a et des formulations comprenant l'arn modifié. Des aspects de l'invention concernent en outre des préparations et des utilisations de formulations comprenant l'arn modifié dans le traitement de sujets souffrant de maladies sensibles à une thérapie par vegf-a.
MA45172A 2016-06-07 2017-06-06 Arn modifié codant pour des polypeptides vegf-a, formulations et utilisations associées MA45172B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662346979P 2016-06-07 2016-06-07
US201662411091P 2016-10-21 2016-10-21
US201662432005P 2016-12-09 2016-12-09
PCT/US2017/036188 WO2017214175A1 (fr) 2016-06-07 2017-06-06 Arn modifié codant pour des polypeptides vegf-a, formulations et utilisations associées

Publications (2)

Publication Number Publication Date
MA45172A MA45172A (fr) 2019-04-10
MA45172B1 true MA45172B1 (fr) 2021-11-30

Family

ID=59270113

Family Applications (1)

Application Number Title Priority Date Filing Date
MA45172A MA45172B1 (fr) 2016-06-07 2017-06-06 Arn modifié codant pour des polypeptides vegf-a, formulations et utilisations associées

Country Status (24)

Country Link
US (1) US11866475B2 (fr)
EP (2) EP3464338B1 (fr)
JP (3) JP6859369B2 (fr)
KR (4) KR102376245B1 (fr)
CN (2) CN109790207B (fr)
AU (2) AU2017277277B2 (fr)
CA (1) CA3026500A1 (fr)
CY (1) CY1124667T1 (fr)
DK (1) DK3464338T3 (fr)
ES (1) ES2895421T3 (fr)
HR (1) HRP20211569T1 (fr)
HU (1) HUE056055T2 (fr)
IL (1) IL263370A (fr)
LT (1) LT3464338T (fr)
MA (1) MA45172B1 (fr)
MX (1) MX2018015110A (fr)
PL (1) PL3464338T3 (fr)
PT (1) PT3464338T (fr)
RS (1) RS62556B1 (fr)
RU (1) RU2756313C2 (fr)
SG (2) SG10202012175YA (fr)
SI (1) SI3464338T1 (fr)
TW (2) TWI818375B (fr)
WO (1) WO2017214175A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2756313C2 (ru) 2016-06-07 2021-09-29 Модернатикс, Инк. Модифицированная РНК, кодирующая полипептиды VEGF-A, составы, содержащие ее, и пути их применения
US11628227B2 (en) * 2017-07-05 2023-04-18 Wisconsin Alumni Research Foundation Mineral coated microparticles for gene delivery in chronic wound therapy
IL274230B2 (en) * 2017-10-31 2023-12-01 Modernatx Inc Lipid nanoparticles for delivery of modified RNA encoding VEGF-A polypeptide
CN114173826A (zh) * 2019-05-08 2022-03-11 阿斯利康(瑞典)有限公司 使用脂质纳米颗粒用于递送编码vegf-a多肽的经修饰的rna的方法和包含其的药物组合物
JP7345888B2 (ja) * 2021-06-17 2023-09-19 株式会社ニューギン 遊技機
WO2023061985A2 (fr) * 2021-10-12 2023-04-20 Modernatx, Inc. Compositions comprenant un arn modifié codant pour vegf-a et procédés d'utilisation
WO2023084013A1 (fr) * 2021-11-12 2023-05-19 Modernatx, Inc. Compositions comprenant un arn modifié codant vegf-a et méthodes d'utilisation

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004035227A1 (de) * 2004-07-21 2006-02-16 Curevac Gmbh mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen
WO2006086798A2 (fr) 2005-02-08 2006-08-17 Board Of Regents, The University Of Texas System Compositions et methodes faisant intervenir la proteine mda-7 pour le traitement du cancer
US9034316B2 (en) 2006-10-24 2015-05-19 Amorcyte, Llc Infarct area perfusion-improving compositions and methods of vascular injury repair
WO2010065671A2 (fr) 2008-12-04 2010-06-10 Curna, Inc. Traitement de maladies apparentées au facteur de croissance de l'endothélium vasculaire (vegf) par inhibition de la transcription antisens naturelle en vegf
WO2011069529A1 (fr) * 2009-12-09 2011-06-16 Curevac Gmbh Solution contenant du mannose pour la lyophilisation, la transfection et/ou l'injection d'acides nucléiques
EP2651445A2 (fr) 2010-12-16 2013-10-23 SPRNA GmbH Composition pharmaceutique à base d'arn qui comprend un métal alcalin en tant que contre-ion et formulé avec des dications
EP2691101A2 (fr) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Administration et formulation d'acides nucléiques génétiquement modifiés
EP2694660B1 (fr) 2011-04-03 2018-08-08 The General Hospital Corporation Expression protéique efficace in vivo à l'aide d'arn modifié (mod-arn)
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
AU2012358384A1 (en) 2011-12-21 2014-07-31 Moderna Therapeutics, Inc. Methods of increasing the viability or longevity of an organ or organ explant
US10501513B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
CA2868398A1 (fr) 2012-04-02 2013-10-10 Moderna Therapeutics, Inc. Polynucleotides modifies pour la production de proteines et de peptides cosmetiques
US20140275229A1 (en) * 2012-04-02 2014-09-18 Moderna Therapeutics, Inc. Modified polynucleotides encoding udp glucuronosyltransferase 1 family, polypeptide a1
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9663564B2 (en) 2013-03-15 2017-05-30 The Regents Of The University Of California Vectors and methods to treat ischemia
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
WO2015024667A1 (fr) 2013-08-21 2015-02-26 Curevac Gmbh Procédé pour augmenter l'expression de protéines codées par l'arn
WO2015107026A1 (fr) * 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Variants de région fc présentant des propriétés modifiées de liaison à fcrn et des propriétés conservées de liaison à la protéine a
EP3247398A4 (fr) 2015-01-23 2018-09-26 Moderna Therapeutics, Inc. Compositions de nanoparticules lipidiques
AU2016324310B2 (en) 2015-09-17 2021-04-08 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
RU2756313C2 (ru) 2016-06-07 2021-09-29 Модернатикс, Инк. Модифицированная РНК, кодирующая полипептиды VEGF-A, составы, содержащие ее, и пути их применения
WO2018104540A1 (fr) 2016-12-08 2018-06-14 Curevac Ag Arn pour la cicatrisation des plaies
MX2016016339A (es) 2016-12-09 2018-06-08 Desarrolladora Y Com De Tecnologias Biomedicas Decotecbio S A S De C V Composicion coadyuvante de un factor de crecimiento y un neuropeptido para acelerar la cicatrizacion de heridas y la repitelizacion de organos.
IL274230B2 (en) 2017-10-31 2023-12-01 Modernatx Inc Lipid nanoparticles for delivery of modified RNA encoding VEGF-A polypeptide
JP2022532078A (ja) 2019-05-08 2022-07-13 アストラゼネカ アクチボラグ 皮膚及び創傷のための組成物並びにその使用の方法

Also Published As

Publication number Publication date
SI3464338T1 (sl) 2022-02-28
ES2895421T3 (es) 2022-02-21
KR20230107891A (ko) 2023-07-18
PT3464338T (pt) 2021-10-19
TWI752036B (zh) 2022-01-11
JP2019521976A (ja) 2019-08-08
DK3464338T3 (da) 2021-10-18
CA3026500A1 (fr) 2017-12-14
PL3464338T3 (pl) 2021-12-27
EP3971204A1 (fr) 2022-03-23
KR102376245B1 (ko) 2022-03-21
RS62556B1 (sr) 2021-12-31
HRP20211569T1 (hr) 2022-01-21
RU2756313C2 (ru) 2021-09-29
EP3464338B1 (fr) 2021-07-21
EP3464338A1 (fr) 2019-04-10
TWI818375B (zh) 2023-10-11
MX2018015110A (es) 2019-09-06
JP2023011733A (ja) 2023-01-24
KR20230019505A (ko) 2023-02-08
US20200407411A1 (en) 2020-12-31
SG10202012175YA (en) 2021-01-28
JP6859369B2 (ja) 2021-04-14
JP2021100961A (ja) 2021-07-08
CY1124667T1 (el) 2022-07-22
AU2023208200A1 (en) 2023-08-17
CN109790207A (zh) 2019-05-21
IL263370A (en) 2018-12-31
US11866475B2 (en) 2024-01-09
KR102552543B1 (ko) 2023-07-06
CN116606861A (zh) 2023-08-18
KR102494499B1 (ko) 2023-01-31
LT3464338T (lt) 2022-01-10
HUE056055T2 (hu) 2022-01-28
JP7167226B2 (ja) 2022-11-08
AU2017277277A1 (en) 2019-01-03
SG11201810816QA (en) 2018-12-28
CN109790207B (zh) 2023-06-20
MA45172A (fr) 2019-04-10
TW201808325A (zh) 2018-03-16
KR20190039066A (ko) 2019-04-10
RU2018147229A3 (fr) 2020-09-23
WO2017214175A1 (fr) 2017-12-14
AU2017277277B2 (en) 2023-05-04
RU2018147229A (ru) 2020-07-10
KR20220038819A (ko) 2022-03-29
TW202218670A (zh) 2022-05-16

Similar Documents

Publication Publication Date Title
MA45172B1 (fr) Arn modifié codant pour des polypeptides vegf-a, formulations et utilisations associées
MA47313B1 (fr) Formulations sous-cutanées d'anticorps her2
MA40755B1 (fr) Compositions comprenant des souches bactériennes
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
BR112018068189A2 (pt) proteínas de ligação induzíveis e métodos de uso
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
MA45029B1 (fr) Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer
MA41060B1 (fr) Compositions comprenant des souches bactériennes
WO2017134302A3 (fr) Agents thérapeutiques ciblés et leurs utilisations
ATE516814T1 (de) 10fn3 domain zur behandlung von krankheiten begleitet von unerwünschter angiogenese
EA201792047A1 (ru) Новые соединения
EA201890006A1 (ru) Применение экзосом для лечения болезни
MY196882A (en) Recombinant binding proteins and their use
MA41010A (fr) Compositions comprenant des souches bactériennes
MA38478A1 (fr) Anticorps anti-pac1 humains
MX2017014730A (es) Muteinas de lipocalina 2 humana con afinidad por glipicano-3 (gpc3).
MX2019003805A (es) Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías.
AU2018264384A1 (en) Solid forms of berberine ursodeoxycholate and compositions and methods thereof
MA39342B2 (fr) Anticorps il -21
BR112016030774A2 (pt) anticorpo ou fragmento de ligação a antígeno do mesmo, uso de um anticorpo, métodos para redução da quantidade de protofibrilas de ?? em um indivíduo, para tratamento e/ou para profilaxia de uma doença, para medição da quantidade de protofibrilas de ?? e/ou de proteína ?? agregada em uma pessoa, e para diagnóstico de uma doença, e, composição farmacêutica
EA201992688A1 (ru) Средства, пути применения и способы лечения
EA202190310A1 (ru) Белок для лечения воспалительных заболеваний
MX2017012397A (es) Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache).
MA38485A1 (fr) Anticorps anti-cd52 humains pour une utilisation dans le traitement, par exemple, des maladies auto-immunes, le cancer, et le rejet de greffe
FR3063645B1 (fr) Acefapc pour le traitement des maladies acetylcholine dependantes